Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lodo Therapeutics launches with $17mm Series A investment

Executive Summary

Newly launched Lodo Therapeutics Corp. (naturally-derived, genetically-encoded small-molecule drugs) raised $17mm in Series A funds from life science investment firm Accelerator Corp., AbbVie, Alexandria Venture Investments, Arch Venture Partners, Eli Lilly, Harris & Harris Group, Innovate NY Fund, Johnson & Johnson Innovation (JJDC), The Partnership Fund for New York City, Pfizer Venture Investments, Watson Fund, WuXi PharmaTech, and the Bill & Melinda Gates Foundation.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies